Header Logo

Connection

Jeff Slezak to Neoplasm Recurrence, Local

This is a "connection" page, showing publications Jeff Slezak has written about Neoplasm Recurrence, Local.
Connection Strength

1.187
  1. Risk factors for locoregional recurrence after mastectomy in stage T1 N0 breast cancer. Am J Clin Oncol. 2014 Oct; 37(5):486-91.
    View in: PubMed
    Score: 0.408
  2. Salvage Cryoablation for Radiorecurrent Prostate Cancer: Initial Experience at a Regional Health Care System. Perm J. 2019; 23.
    View in: PubMed
    Score: 0.137
  3. Observation versus adjuvant radiation or chemotherapy in the management of stage I seminoma: clinical outcomes and prognostic factors for relapse in a large US cohort. Am J Clin Oncol. 2014 Aug; 37(4):356-9.
    View in: PubMed
    Score: 0.101
  4. Comparison of biochemical failure rates between permanent prostate brachytherapy and radical retropubic prostatectomy as a function of posttherapy PSA nadir plus 'X'. Radiat Oncol. 2014 Jul 29; 9:171.
    View in: PubMed
    Score: 0.101
  5. Locally recurrent prostate cancer after initial radiation therapy: a comparison of salvage radical prostatectomy versus cryotherapy. J Urol. 2009 Aug; 182(2):517-25; discussion 525-7.
    View in: PubMed
    Score: 0.071
  6. The impact of surgical approach (nerve bundle preservation versus wide local excision) on surgical margins and biochemical recurrence following radical prostatectomy. J Urol. 2004 Oct; 172(4 Pt 1):1328-32.
    View in: PubMed
    Score: 0.051
  7. Surgical treatment for local control of female urethral carcinoma. Urol Oncol. 2004 Sep-Oct; 22(5):404-9.
    View in: PubMed
    Score: 0.051
  8. The long-term clinical impact of biochemical recurrence of prostate cancer 5 or more years after radical prostatectomy. J Urol. 2003 Nov; 170(5):1872-6.
    View in: PubMed
    Score: 0.048
  9. Contemporary identification of patients at high risk of early prostate cancer recurrence after radical retropubic prostatectomy. Urology. 2001 Jun; 57(6):1033-7.
    View in: PubMed
    Score: 0.040
  10. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer. Mayo Clin Proc. 2001 Jun; 76(6):576-81.
    View in: PubMed
    Score: 0.040
  11. Role of microvessel density in predicting recurrence in pathologic Stage T3 prostatic adenocarcinoma. Urology. 1999 Sep; 54(3):479-85.
    View in: PubMed
    Score: 0.036
  12. p53 protein overexpression is associated with increased cell proliferation in patients with locally recurrent prostate carcinoma after radiation therapy. Cancer. 1999 Mar 15; 85(6):1293-9.
    View in: PubMed
    Score: 0.035
  13. Is the GPSM scoring algorithm for patients with prostate cancer valid in the contemporary era? J Urol. 2007 Aug; 178(2):459-63; discussion 463.
    View in: PubMed
    Score: 0.015
  14. Stratification of patient risk based on prostate-specific antigen doubling time after radical retropubic prostatectomy. Mayo Clin Proc. 2007 Apr; 82(4):422-7.
    View in: PubMed
    Score: 0.015
  15. Prognostic significance of positive surgical margins in patients with extraprostatic carcinoma after radical prostatectomy. Cancer. 2002 Sep 15; 95(6):1215-9.
    View in: PubMed
    Score: 0.011
  16. Efficacy of contralateral prophylactic mastectomy in women with a personal and family history of breast cancer. J Clin Oncol. 2001 Oct 01; 19(19):3938-43.
    View in: PubMed
    Score: 0.010
  17. Long-term hazard of progression after radical prostatectomy for clinically localized prostate cancer: continued risk of biochemical failure after 5 years. J Urol. 2000 Jul; 164(1):101-5.
    View in: PubMed
    Score: 0.009
  18. Anatomic site-specific positive margins in organ-confined prostate cancer and its impact on outcome after radical prostatectomy. Urology. 1997 Nov; 50(5):733-9.
    View in: PubMed
    Score: 0.008

© 2024 Kaiser Permanente